Liang Geyu, Pu Yuepu, Yin Lihong, Liu Ran, Ye Bing, Su Yaoyao, Li Yanfen
School of Public Health, Southeast University, Nanjing, People's Republic of China.
J Toxicol Environ Health A. 2009;72(11-12):740-5. doi: 10.1080/15287390902841516.
As titanium dioxide (TiO(2)) nanoparticles are widely used commercially, the potential effects of TiO(2) nanoparticles on humans are a concern. To evaluate the effects of TiO(2) nanoparticles on hepatic and renal functions and correlate changes to oxidative stress, Sprague-Dawley rats were treated with TiO(2) particles of two different specific surface areas (TiO(2-S50): 50 m(2)/g, and TiO(2-S210): 210 m(2)/g) at 0.5, 5, or 50 mg/kg body weight by intratracheal instillation. After 7 d, TiO(2) nanoparticles produced no obvious acute toxicity on hepatic and renal functions. However, superoxide dismutase (SOD) activity of plasma and glutathione peroxidase (GSH-PX) activity of kidney in the low-dose TiO(2-S210) group were significantly decreased. After TiO(2-S210) exposure, malondialdehyde (MDA) levels of liver and kidney in intermediate and high-dose groups were significantly increased. This change only appeared in liver after TiO(2-S50) exposure. Furthermore, SOD activity in liver and kidney and GSH-PX activity in kidney with low TiO(2-S210) exposure group were significantly less than with low TiO(2-S50). No apparent pathological changes in liver and kidney were observed. Intratracheal exposure to TiO(2) nanoparticles may induce oxidative stress in liver and kidney, but does not influence hepatic or renal functions. There was no apparent evidence that TiO(2-S210) was more toxic than TiO(2-S50). In general, intratracheal exposure to TiO(2) did not markedly affect extrapulmonary tissue functions.
由于二氧化钛(TiO₂)纳米颗粒在商业上被广泛使用,其对人类的潜在影响备受关注。为了评估TiO₂纳米颗粒对肝脏和肾脏功能的影响,并将这些变化与氧化应激相关联,通过气管内滴注,用两种不同比表面积的TiO₂颗粒(TiO₂-S50:50 m²/g,和TiO₂-S210:210 m²/g)以0.5、5或50 mg/kg体重的剂量处理Sprague-Dawley大鼠。7天后,TiO₂纳米颗粒对肝脏和肾脏功能未产生明显的急性毒性。然而,低剂量TiO₂-S210组血浆中的超氧化物歧化酶(SOD)活性和肾脏中的谷胱甘肽过氧化物酶(GSH-PX)活性显著降低。TiO₂-S210暴露后,中、高剂量组肝脏和肾脏中的丙二醛(MDA)水平显著升高。TiO₂-S50暴露后,这种变化仅出现在肝脏中。此外,低TiO₂-S210暴露组肝脏和肾脏中的SOD活性以及肾脏中的GSH-PX活性显著低于低TiO₂-S50组。在肝脏和肾脏中未观察到明显的病理变化。气管内暴露于TiO₂纳米颗粒可能会诱导肝脏和肾脏中的氧化应激,但不会影响肝脏或肾脏功能。没有明显证据表明TiO₂-S210比TiO₂-S50毒性更大。总体而言,气管内暴露于TiO₂对肺外组织功能没有明显影响。